GB0127145D0
(en)
|
2001-11-10 |
2002-01-02 |
Smithkline Beecham |
Compounds
|
HUP0400405A3
(en)
*
|
2004-02-10 |
2009-03-30 |
Sanofi Synthelabo |
Pyrimidine derivatives, process for producing them, their use, pharmaceutical compositions containing them and their intermediates
|
AU2005250077B2
(en)
|
2004-03-01 |
2011-06-09 |
Idorsia Pharmaceuticals Ltd |
Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
|
KR20090077051A
(en)
*
|
2006-09-29 |
2009-07-14 |
액테리온 파마슈티칼 리미티드 |
3-aza-bicyclo[3.1.0]hexane derivatives
|
EP2094685B1
(en)
|
2006-12-01 |
2011-01-19 |
Actelion Pharmaceuticals Ltd. |
3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperdine derivatives as orexin receptor inhibitors
|
TW200833328A
(en)
*
|
2006-12-28 |
2008-08-16 |
Actelion Pharmaceuticals Ltd |
2-aza-bicyclo[3.1.0]hexane derivatives
|
WO2008087611A2
(en)
*
|
2007-01-19 |
2008-07-24 |
Actelion Pharmaceuticals Ltd |
Pyrrolidine- and piperidine- bis-amide derivatives
|
CL2008000836A1
(en)
|
2007-03-26 |
2008-11-07 |
Actelion Pharmaceuticals Ltd |
Thiazolidine derivative compounds, orexin receptor antagonists; pharmaceutical composition that includes them; and its use in the treatment of emotional neurosis, severe depression, psychotic disorders, Alzheimer's, parkinson's, pain, among others.
|
PT2152690E
(en)
|
2007-05-23 |
2012-03-30 |
Merck Sharp & Dohme |
Pyridyl piperidine orexin receptor antagonists
|
ES2371514T3
(en)
*
|
2007-07-03 |
2012-01-04 |
Actelion Pharmaceuticals Ltd. |
3-AZA-BICYCLE COMPOUNDS [3.3.0] OCTANO.
|
KR20100046047A
(en)
|
2007-07-27 |
2010-05-04 |
액테리온 파마슈티칼 리미티드 |
2-aza-bicyclo[3.3.0]octane derivatives
|
WO2009040730A2
(en)
|
2007-09-24 |
2009-04-02 |
Actelion Pharmaceuticals Ltd |
Pyrrolidines and piperidines as orexin receptor antagonists
|
AU2009215243A1
(en)
|
2008-02-21 |
2009-08-27 |
Actelion Pharmaceuticals Ltd. |
2-aza-bicyclo[2.2.1]heptane derivatives
|
WO2010047982A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
CA2741672A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2011050202A1
(en)
|
2009-10-23 |
2011-04-28 |
Janssen Pharmaceutica Nv |
Fused heterocyclic compounds as orexin receptor modulators
|
EP2491034B1
(en)
|
2009-10-23 |
2013-12-18 |
Janssen Pharmaceutica, N.V. |
Fused heterocyclic compounds as orexin receptor modulators
|
CN102781942B
(en)
|
2009-10-23 |
2015-09-23 |
詹森药业有限公司 |
Octahydro pyrrolo-[3,4-c] pyrroles is replaced as two of orexin receptor modulators
|
WO2011103126A1
(en)
*
|
2010-02-17 |
2011-08-25 |
Ampla Pharmaceuticals Inc. |
Treatment of metabolic syndrome with piperidine amides
|
WO2011106273A1
(en)
|
2010-02-25 |
2011-09-01 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
EA025380B1
(en)
|
2011-02-25 |
2016-12-30 |
Мерк Шарп Энд Домэ Корп. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
WO2012145581A1
(en)
|
2011-04-20 |
2012-10-26 |
Janssen Pharmaceutica Nv |
Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators
|
WO2013119639A1
(en)
|
2012-02-07 |
2013-08-15 |
Eolas Therapeutics, Inc. |
Substituted prolines / piperidines as orexin receptor antagonists
|
US9440982B2
(en)
|
2012-02-07 |
2016-09-13 |
Eolas Therapeutics, Inc. |
Substituted prolines/piperidines as orexin receptor antagonists
|
TWI570120B
(en)
|
2012-06-04 |
2017-02-11 |
艾克泰聯製藥有限公司 |
Benzimidazole-proline derivatives
|
KR20150036245A
(en)
|
2012-08-02 |
2015-04-07 |
머크 샤프 앤드 돔 코포레이션 |
Antidiabetic tricyclic compounds
|
EA201500399A1
(en)
|
2012-10-10 |
2015-09-30 |
Актелион Фармасьютиклз Лтд. |
OREXIN RECEPTOR ANTAGONISTS, WHICH ARE REPRESENTING DERIVATIVES OF [ORTO-BI- (HETERO) ARYL] - [2- (META-BI- (HETERO) ARYL) PYRROLIDIN-1-IL] METHANON
|
RU2015140066A
(en)
|
2013-02-22 |
2017-03-30 |
Мерк Шарп И Доум Корп. |
ANTI-DIABETIC BICYCLIC COMPOUNDS
|
KR20150130413A
(en)
|
2013-03-12 |
2015-11-23 |
액테리온 파마슈티칼 리미티드 |
Azetidine amide derivatives as orexin receptor antagonists
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
UA119151C2
(en)
|
2013-12-03 |
2019-05-10 |
Ідорсія Фармасьютікалз Лтд |
Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1 h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
|
KR102361418B1
(en)
|
2013-12-03 |
2022-02-09 |
이도르시아 파마슈티컬스 리미티드 |
Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists
|
KR102330133B1
(en)
|
2013-12-04 |
2021-11-23 |
이도르시아 파마슈티컬스 리미티드 |
Use of benzimidazole-proline derivatives
|
UY36272A
(en)
|
2014-08-13 |
2016-02-29 |
Eolas Therapeutics Inc |
DIFLUOROPIRROLIDINS AS MODULATORS OF OREXIN RECEPTORS
|
EP3414241B1
(en)
|
2016-02-12 |
2022-05-04 |
Astrazeneca AB |
Halo-substituted piperidines as orexin receptor modulators
|
CN108883110B
(en)
|
2016-03-10 |
2022-05-27 |
詹森药业有限公司 |
Methods of treating depression using orexin-2 receptor antagonists
|
US20190151304A1
(en)
|
2016-05-10 |
2019-05-23 |
Inserm (Institut National De La Santé Et De La Rechercjae Médicale |
Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory
|
US11072602B2
(en)
|
2016-12-06 |
2021-07-27 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
US10968232B2
(en)
|
2016-12-20 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
GB201702174D0
(en)
|
2017-02-09 |
2017-03-29 |
Benevolentai Bio Ltd |
Orexin receptor antagonists
|
GB201707504D0
(en)
|
2017-05-10 |
2017-06-21 |
Benevolentai Bio Ltd |
Orexin receptor antagonists
|
GB201707499D0
(en)
|
2017-05-10 |
2017-06-21 |
Benevolentai Bio Ltd |
Orexin receptor antagonists
|
WO2020007964A1
(en)
|
2018-07-05 |
2020-01-09 |
Idorsia Pharmaceuticals Ltd |
2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
|
WO2020099511A1
(en)
|
2018-11-14 |
2020-05-22 |
Idorsia Pharmaceuticals Ltd |
Benzimidazole-2-methyl-morpholine derivatives
|
WO2023218023A1
(en)
|
2022-05-13 |
2023-11-16 |
Idorsia Pharmaceuticals Ltd |
Thiazoloaryl-methyl substituted cyclic hydrazine-n-carboxamide derivatives
|